KaloBios Pharma (KBIO) Tops Q2 EPS by 22c

KaloBios Pharma (NASDAQ: KBIO) reported Q2 EPS of ($1.46), $0.22 better than the analyst estimate of ($1.68).

For earnings history and earnings-related data on KaloBios Pharma (KBIO) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56
• Marvell (MRVL) Stock: Risk/Reward Skewed to the Upside Near-Term Following Selloff, Says Analyst